Our development portfolio includes novel oncology and supportive care product candidates.

Registration
Phase 3
Phase 2
Phase 1
Pre-Clinical
Discovery
Compound
Indication
Phase
Rolapitant(IV)
Niraparib + bevacizumab
Niraparib + chemotherapy
TSR-042 (anti-PD-1 mAb)
TSR-022 (anti-TIM-3 mAb)
TSR-033
(anti-LAG-3 mAb)
Anti-TIM-3/PD-1 antibody
Anti-LAG-3/PD-1 antibody
Undisclosed antibody
Undisclosed small molecule I-O candidates

* In collaboration with ENGOT, the European Network for Gynaecological Oncological Trial groups
** In collaboration with SARC, the Sarcoma Alliance for Research through Collaboration

Upon successful development and regulatory approval of any of our product candidates we intend to make them available to cancer patients in North America, Europe and China through our own commercialization efforts and to establish a network of licensees and distributors in other geographic areas.


Clinical Trials

The links below will provide you with information regarding TESARO's ongoing clinical trials.

  • A Phase 3 Ovarian Cancer Maintenance Treatment Study (NOVA):
    NCT01847274

    A Study of Niraparib Maintenance Treatment in Patients With HRD-Positive Advanced Ovarian Cancer Following Response on Front-Line Platinum-Based Chemotherapy (PRIMA:)
    NCT02655016

    A Phase 3 Study in Germline BRCA Mutation-Positive Breast Cancer Patients (BRAVO):
    NCT01905592

    A Study of Niraparib in Patients With Ovarian Cancer Who Have Received at Least Three Previous Chemotherapy Regimens (QUADRA):
    NCT02354586

    Niraparib and/or Niraparib-Bevacizumab Combination Against Bevacizumab Alone in Platinum-Sensitive Ovarian Cancer (AVANOVA):
    NCT02354131

    A Study of Niraparib in Combination With Pembrolizumab (MK-3475) in Patients With Triple-negative Breast Cancer or Ovarian Cancer (TOPACIO):
    NCT02657889

    A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-042, an Anti-PD-1 Monoclonal Antibody, in Patients With Advanced Solid Tumors:
    NCT02715284

    A Phase 1 Study of TSR-022, an Anti-TIM-3 Monoclonal Antibody, in Patients With Advanced Solid Tumors:
    NCT02817633

  • For Medical Information
    Requests Only:


    Click here to request Medical Information
You are now leaving this website. If you would like to continue, click Continue.
CancelContinue